Does Regence Cover Eliquis?

How Regence Classifies Eliquis on Its Formulary

Regence Blue Cross Blue Shield operates across Oregon, Washington, Idaho, and Utah, offering commercial group, individual marketplace, and Medicare Advantage prescription drug plans. On the majority of these plans, Eliquis (apixaban) sits on the preferred brand tier, which is typically Tier 3 on a four- or five-tier formulary structure.

Preferred brand placement matters because it directly controls your out-of-pocket cost. A Tier 3 drug on a Regence commercial PPO, for example, usually carries a fixed copay between $35 and $75. Some high-deductible health plans (HDHPs) require the member to meet the full deductible before any copay applies, which can mean paying the pharmacy's discounted rate of roughly $550 to $620 per month until that threshold is reached 1.

Regence updates its formularies quarterly. The 2026 formulary documents published on the Regence member portal confirm Eliquis remains listed without a mandatory step-therapy requirement on most commercial plans. However, a small number of self-funded employer groups customize their drug lists independently, so your specific Summary of Benefits and Coverage (SBC) is the definitive document.

What Eliquis Is Prescribed For

Apixaban is a direct oral anticoagulant (DOAC) approved by the FDA for four indications: reducing the risk of stroke and systemic embolism in nonvalvular atrial fibrillation, treating deep vein thrombosis (DVT) and pulmonary embolism (PE), preventing recurrent DVT/PE, and preventing DVT after hip or knee replacement surgery 1.

The ARISTOTLE trial (N=18,201) established apixaban's efficacy in atrial fibrillation, demonstrating a 21% relative risk reduction in stroke or systemic embolism compared with warfarin (1.27% vs. 1.60% per year, P<0.001 for noninferiority) and a 31% reduction in major bleeding (2.13% vs. 3.09% per year, P<0.001) 2. These results are the clinical foundation for why Regence and other large insurers maintain Eliquis on preferred tiers rather than restricting it behind step therapy.

For venous thromboembolism, the AMPLIFY trial (N=5,395) showed apixaban was noninferior to conventional enoxaparin-plus-warfarin therapy for recurrent VTE (2.3% vs. 2.7%) while producing 69% less major bleeding (0.6% vs. 1.8%, P<0.001) 3. That bleeding advantage is a primary reason prescribers favor apixaban for patients who are older or have renal impairment.

Prior Authorization and Step Therapy Details

Not every Regence member needs prior authorization (PA) for Eliquis, but certain plan types do require it. PA is most commonly triggered for DVT prophylaxis after orthopedic surgery, where Regence may request documentation of the specific procedure and the planned duration of anticoagulation (typically 12 days for knee replacement and 35 days for hip replacement per the American College of Chest Physicians 2012 guidelines) [4].

For atrial fibrillation and active VTE treatment, most Regence commercial plans approve Eliquis without PA. Medicare Advantage plans administered by Regence follow CMS formulary requirements and may apply utilization management edits, including quantity limits of 60 tablets per 30-day fill.

If your claim is denied, Regence provides two appeal pathways. The standard appeal takes up to 30 calendar days. An expedited appeal, appropriate when delaying treatment could seriously harm the patient, must be resolved within 72 hours. The 2024 ACC/AHA/ACCP/HRS guideline for atrial fibrillation management specifically recommends DOACs over warfarin as first-line therapy (Class I, Level of Evidence A), which strengthens any appeal argument for Eliquis coverage 5.

As the guideline states: "For patients with AF who are appropriate for oral anticoagulation, a DOAC is recommended over a vitamin K antagonist" 5. Citing this language directly in a letter of medical necessity can accelerate approval.

What You Will Actually Pay

Out-of-pocket costs for Eliquis through Regence depend on three variables: your plan tier structure, whether you have met your deductible, and whether you use a manufacturer copay assistance program.

Commercial PPO/HMO plans. Most Regence commercial members with a standard copay design pay $35 to $90 per 30-day supply at a preferred pharmacy. Using a Regence-preferred mail-order pharmacy (typically Express Scripts or a contracted specialty pharmacy) can reduce the copay by $5 to $15 per fill.

High-deductible health plans. Members on HDHPs pay the negotiated pharmacy rate (often $540 to $620 for a 30-day supply) until the annual deductible is met. After that, coinsurance of 20% to 30% applies, bringing the monthly cost to approximately $110 to $185.

Medicare Advantage. Regence Medicare Advantage Part D plans place Eliquis on the preferred brand tier at $47 to $150 per month during the initial coverage phase. Once the member reaches the coverage gap, the manufacturer discount of 70% under the Inflation Reduction Act brings the effective cost down considerably. After the $2,000 annual out-of-pocket cap (effective since 2025), members pay $0 for the remainder of the year 6.

Bristol Myers Squibb copay card. Commercially insured patients (not Medicare, Medicaid, or other federal program beneficiaries) may qualify for the manufacturer's copay assistance program, reducing the monthly cost to as low as $10. The program covers up to $6,400 per year in copay assistance. Enrollment is available at the official Eliquis website or through the prescriber's office.

Generic Apixaban: Current Status

As of May 2026, no generic version of apixaban has reached the U.S. market. Bristol Myers Squibb and Pfizer hold patents that have been the subject of extensive litigation. Several generic manufacturers, including Teva, Aurobindo, and Micro Labs, have received tentative FDA approvals, but patent settlements have delayed commercial launch.

The earliest projected generic entry is late 2026 to early 2027 based on published settlement terms. When a generic does launch, Regence will likely move it to a lower formulary tier (Tier 1 or Tier 2), dramatically reducing copays to the $5 to $25 range that is standard for generic preferred drugs.

Until then, the combination of Regence's preferred brand tier placement and the manufacturer copay card remains the most cost-effective approach for most commercially insured patients.

How Eliquis Compares to Other Covered Blood Thinners

Regence formularies typically cover three DOACs: Eliquis (apixaban), Xarelto (rivarboxaban), and Pradaxa (dabigatran). Savaysa (edoxaban) is covered but often placed on a higher, non-preferred tier. Warfarin remains available at Tier 1 with copays under $10.

The choice between DOACs is clinical, not just financial. The ARISTOTLE trial showed apixaban had lower rates of major bleeding than warfarin 2. The ROCKET AF trial (N=14,264) demonstrated rivaroxaban's noninferiority to warfarin for stroke prevention, but without a statistically significant reduction in major bleeding (3.6% vs. 3.4%, P=0.58) 7. A 2022 retrospective cohort study published in the Annals of Internal Medicine (N=581,451) found that apixaban was associated with lower rates of major bleeding compared with rivaroxaban (HR 0.58 to 95% CI 0.56 to 0.60) in a real-world Medicare population 8.

Dr. Renato Lopes, a lead investigator on ARISTOTLE and professor of medicine at Duke University Medical Center, noted: "The totality of evidence supports apixaban as having the most favorable bleeding profile among the available DOACs, which is particularly important in elderly patients and those with moderate renal impairment" 2.

For patients where cost is the primary barrier, Xarelto's once-daily dosing may improve adherence, and Pradaxa has its own manufacturer savings program. But if your Regence plan covers all three at the same tier, the bleeding-risk data favors apixaban for most clinical scenarios.

Tips for Reducing Your Eliquis Cost on Regence

Practical steps can significantly lower what you pay each month. These apply whether you are on a commercial, marketplace, or Medicare Advantage Regence plan.

Use the Regence preferred pharmacy network. Filling at an out-of-network pharmacy can double or triple your copay. Log into the Regence member portal or call the number on your card to confirm which pharmacies are preferred.

Enroll in the manufacturer copay card. For commercial members, this is the single highest-impact cost reduction available. It takes the copay down to $10 in most cases and can be combined with Regence's negotiated rate.

Request 90-day mail-order fills. Many Regence plans offer a cost advantage for 90-day supplies through mail-order, effectively giving you three months for the price of two copays.

Ask about Extra Help (Medicare members). The Social Security Administration's Low Income Subsidy program can reduce Part D copays to $4.50 or $11.20 per prescription for qualifying Medicare beneficiaries 6.

File a formulary exception if placed on a high tier. If your Regence plan places Eliquis on a non-preferred tier, your prescriber can submit a formulary exception request. Include the ACC/AHA guideline recommendation for DOACs over warfarin and any clinical contraindications to alternative agents 5.

When Regence Might Deny Eliquis Coverage

Denials are uncommon for standard AFib and VTE indications, but they do happen. The most frequent denial reasons on Regence plans include: the member has not yet tried warfarin on a plan that still enforces step therapy (rare but present in some self-funded groups), the prescribed dose does not match FDA labeling for the stated diagnosis, or the quantity exceeds the plan's dispensing limit.

Dose verification is a common sticking point. The FDA-approved dose for AFib is 5 mg twice daily, with a reduced dose of 2.5 mg twice daily for patients meeting at least two of these three criteria: age 80 years or older, body weight 60 kg or less, or serum creatinine 1.5 mg/dL or higher 1. If a prescriber writes for 2.5 mg twice daily for an AFib patient who does not meet the dose-reduction criteria, Regence's pharmacy benefit manager may flag the claim. The fix is straightforward: the prescriber submits documentation confirming the dose-reduction criteria are met, or adjusts the dose to 5 mg twice daily.

For VTE prophylaxis after joint replacement, some Regence plans require PA with documentation of the surgical date, procedure type, and intended treatment duration. Processing typically takes 24 to 48 hours for standard requests.

Regence Medicare Advantage vs. Commercial Plans: Key Differences

Medicare Advantage plans administered by Regence follow CMS Part D rules, which differ from commercial plan rules in several ways. The $2,000 annual out-of-pocket cap on Part D drugs, in effect since January 2025, means that even patients with high monthly costs for Eliquis will stop paying once they reach that threshold 6. This is a significant change from prior years when the coverage gap could expose members to thousands of dollars in costs.

Commercial Regence plans have no equivalent annual drug out-of-pocket cap (unless the plan's overall out-of-pocket maximum applies to pharmacy). This means commercial members on HDHPs can face sustained high monthly costs until they reach the overall plan maximum, which may be $5,000 to $8,000.

One advantage of commercial plans: eligibility for the manufacturer copay card. Medicare beneficiaries are excluded from this program by federal anti-kickback statutes, making the Part D structure their primary cost-control mechanism.